Literature DB >> 3344993

Pharmacokinetics of bupivacaine following caudal anesthesia in infants.

J X Mazoit1, D D Denson, K Samii.   

Abstract

Pharmacokinetics and protein binding of bupivacaine were studied after caudal injection of 2.5 mg/kg in 13 ASA PS 1 infants (1-6 months of age) scheduled for elective hernia repair. Blood was sampled at frequent intervals from 5 min to 600 min in all but one patients. Additional samples were taken at 720 and 840 min in five patients. Bupivacaine concentration was measured using gas chromatography. Protein binding was measured using ultrafiltration. Peak serum concentrations ranged between 0.55 and 1.93 micrograms/ml. The time to reach the peak ranged from 10 to 60 min. Terminal half-life (T1/2 beta) was 7.7 +/- 2.4h (mean +/- SD), the volume of distribution (Vss) was 3.9 +/- 2.01.kg, and the total body clearance (CL) was 7.1 +/- 3.2 ml.min.kg-1. The free fraction was markedly increased (0.16 +/- 0.07) when compared with published adult values, and showed a highly significant negative correlation with age. Alpha 1 acid glycoprotein measured in the same infants correlated significantly with age. In conclusion, pharmacokinetics of caudal bupivacaine in infants are characterized by Cmax of total drug similar to those observed in adults after epidural injection. The free fraction is increased at least until 6 months of life. This suggests caution in the use of bupivacaine in infants until we understand the clinical significance of this increased free fraction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3344993     DOI: 10.1097/00000542-198803000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

1.  Use of Intralipid in an infant with impending cardiovascular collapse due to local anesthetic toxicity.

Authors:  Shailesh Shah; Senthil Gopalakrishnan; Jesus Apuya; Sonia Shah; Timothy Martin
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

2.  Regional Anesthesia for Pain Relief in Children.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

3.  Continuous caudal anaesthesia with chloroprocaine as an adjunct to general anaesthesia in neonates.

Authors:  J D Tobias; G E Rasmussen; G W Holcomb; J W Brock; W M Morgan
Journal:  Can J Anaesth       Date:  1996-01       Impact factor: 5.063

4.  Pharmacokinetics and systemic toxicity of local anesthetics in children.

Authors:  Yutaka Oda
Journal:  J Anesth       Date:  2016-06-16       Impact factor: 2.078

Review 5.  Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications.

Authors:  Jean-Xavier Mazoit
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Cardiovascular effects of bupivacaine and the role of this agent in preemptive dental analgesia.

Authors:  O J Younessi; A Punnia-Moorthy
Journal:  Anesth Prog       Date:  1999

Review 7.  Clinical pharmacokinetics of epidural and spinal anaesthesia.

Authors:  A G Burm
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

8.  Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.

Authors:  Pankaj K Sethi; Catherine A White; Brian S Cummings; Ronald N Hines; Srinivasa Muralidhara; James V Bruckner
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

Review 9.  Benefit and risks of local anesthetics in infants and children.

Authors:  Joel B Gunter
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 10.  Adverse effects of regional anaesthesia in children.

Authors:  B J Dalens; J X Mazoit
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.